Shares of biotechnology company United Therapeutics (NASDAQ:UTHR)
jumped 11.7% in the afternoon session after the company reported record third-quarter financial results and announced positive outcomes from a key clinical study.
United Therapeutics posts record Q3 2025 revenue of $799.5M, driven by strong Tyvaso growth. The company beat EPS estimates but slightly missed on revenue.
A powerful surge in AI-related stocks — led by a 9% advance in NVIDIA Corp. (NASDAQ:NVDA) over the past two sessions — propelled the S&P 500 above the 6,900 mark and lifted the Nasdaq 100 to 26,100 points, both breaking new records, as investors brace for the Federal Reserve's
Biotechnology company United Therapeutics (NASDAQ:UTHR) fell short of the markets revenue expectations in Q3 CY2025, but sales rose 6.8% year on year to $799.5 million. Its GAAP profit of $7.16 per share was 2.3% above analysts’ consensus estimates.
In a financial landscape often fixated on consistent dividend payouts, United Therapeutics Corporation (NASDAQ: UTHR) stands out with a distinct capital allocation strategy. Contrary to market discussions about "dividend increases," the biotechnology firm has publicly stated it does not anticipate paying dividends in the immediate future. Instead, the company has
United Therapeutics (UTHR) aligns with Peter Lynch's investment strategy, showing strong earnings growth, a fair PEG ratio, and a debt-free balance sheet for long-term value.
United Therapeutics (UTHR) is a strong value stock with a low P/E ratio, zero debt, high profitability, and solid growth, making it an undervalued biotech pick.
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor.
The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
Growth is oxygen.
But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
The stocks featured in this article have all approached their 52-week highs.
When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
United Therapeutics currently trades at $412.41 and has been a dream stock for shareholders. It’s returned 308% since September 2020, tripling the S&P 500’s 103% gain. The company has also beaten the index over the past six months as its stock price is up 29.3%.
United Therapeutics (UTHR) aligns with Peter Lynch's GARP strategy, featuring strong EPS growth, a PEG below 1, zero debt, and robust financial health.
United Therapeutics (UTHR) is a strong value investing candidate with low P/E, zero debt, high profitability, and excellent financial health, offering a solid margin of safety.
